Cue Biopharma, Inc. (CUE) stock

CUENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/30

$16.12−1.38 (-7.89%)

Close on Nov 13, 2026Market cap $117.10MP/E –Yield –

Cue Biopharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cue Biopharma's price to sales ratio was 2.6× on Nov 11, 2026, against 6.9× a year earlier. Over the last 5 years it ranged from 0.8× to 399.8×, with a median of 8.2×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	2.6×	−0.8
2025	Dec 31, 2025	3.3×	−3.5
2024	Dec 31, 2024	6.9×	−24.3
2023	Dec 29, 2023	31.2×	+20.4
2022	Dec 30, 2022	10.8×	−38.7
2021	Dec 31, 2021	49.5×	−52.0
2020	Dec 31, 2020	101.5×	−31.6
2019	Dec 31, 2019	133.1×	–

Where these numbers come from

Parsed from the XBRL in Cue Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Apr 24, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing